Fulgenzi, Claudia; D'Alessio, Antonio; Scheiner, Bernhard et al.
Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunctionJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S586-S586
Weimer, Johannes; Rolef, Peter; Mueller, Lukas et al.
FoCUS cardiac ultrasound training for undergraduates based on current national guidelines: a prospective, controlled, single-center study on transferabilityBMC MEDICAL EDUCATION. Bd. 23. H. 1. 2023
Abou-Alfa, Ghassan K.; Chan, Stephen Lam; Kelley, Kate et al.
FOUR-YEAR OVERALL SURVIVAL UPDATE FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMAHEPATOLOGY. Bd. 78. 2023 S. S90-S91
Goyal, Lipika; Meric-Bernstam, Funda; Hollebecque, Antoine et al.
Futibatinib for FGFR2-Rearranged Intrahepatic CholangiocarcinomaNEW ENGLAND JOURNAL OF MEDICINE. Bd. 388. H. 3. 2023 S. 228-239
Jakobs, Ralf; Moehler, Markus
Gastric carcinoma newsGASTROENTEROLOGIE. Bd. 18. H. 3. 2023 S. 169-171
Harrison, Stephen; Dubourg, Julie; Megnien, Sophie Jeannin et al.
Glycated hemoglobin as an independent predictor of hepatocyte ballooning in non-alcoholic steatohepatitis: combined data from multiple clinical trials including more than 5000 patients (in collaboration with NAIL-NIT consortium)JOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S619-S620
Harrison, Stephen A.; Dubourg, Julie; Jeannin, Sophie et al.
GLYCEMIC CONTROL IMPACTS FIB-4 PERFORMANCE TO PREDICT ADVANCED FIBROSIS AND IS INDEPENDENTLY ASSOCIATED WITH THE PRESENCE OF HEPATOCYTE BALLOONING: COMBINED DATA FROM MULTIPLE THERAPEUTIC TRIALS INCLUDING MORE THAN 6,000 PATIENTS ( IN COLLABORATION WITH NAIL- NIT CONSORTIUM)HEPATOLOGY. Bd. 78. 2023 S. S802-S806
Gross, Sabrina; Bitzer, Michael; Bloedt, Susanne et al.
Guideline report of the S3 guideline diagnostics and therapy of hepatocellular carcinoma and biliary carcinomaZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 61. H. 04. 2023 S. E157-E171
Llovet, Josep M.; Kudo, Masatoshi; Merle, Philippe et al.
Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. 506-506
Elimova, Elena; Wyrwicz, Lucjan; Chen, Clara et al.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/ gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023